Literature DB >> 7029803

Indirect fluorescent antibody test for the diagnosis of yellow fever.

T P Monath, C B Cropp, D J Muth, C H Calisher.   

Abstract

The indirect fluorescent antibody (FA) test was evaluated for the serodiagnosis of yellow fever (YF) cases and for detection of antibodies after 17D YF vaccination. Results were compared with those of standard serological tests, reactions with heterologous flaviviral antigens were determined, and both IgM and IgG antibodies were measured. Spot slides of infected Vero cells were used as antigen substrate. In cases of primary YF infection, the FA test for IgG antibodies provided clear diagnostic results. Indirect FA tests with anti-IgG were more sensitive than the complement-fixation (CF) test and showed specificity comparable to the CF and neutralization (N) test. Cases of YF infection superimposed upon pre-existing heterologous flaviviral immunity developed broadly-crossreactive IgG antibodies. IgM antibodies were highly specific in cases of both primary infection and superinfection but were not consistently present. Most individuals without previous flaviviral exposure who received 17D vaccine failed to develop detectable antibodies by the indirect FA test; of those with pre-existing immunity, 79% developed IgG antibodies. The indirect FA test provides a simple, rapid diagnostic procedure which should be especially useful in one-site epidemiological investigations of YF outbreaks.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7029803     DOI: 10.1016/0035-9203(81)90335-7

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  6 in total

Review 1.  Yellow Fever Virus: Diagnostics for a Persistent Arboviral Threat.

Authors:  Jesse J Waggoner; Alejandra Rojas; Benjamin A Pinsky
Journal:  J Clin Microbiol       Date:  2018-09-25       Impact factor: 5.948

2.  Evaluation of an indirect immunofluorescence assay for detection of immunoglobulin M (IgM) and IgG antibodies against yellow fever virus.

Authors:  Matthias Niedrig; Oliver Kürsteiner; Christian Herzog; Karen Sonnenberg
Journal:  Clin Vaccine Immunol       Date:  2007-11-28

Review 3.  What Does the Future Hold for Yellow Fever Virus? (II).

Authors:  Raphaëlle Klitting; Carlo Fischer; Jan F Drexler; Ernest A Gould; David Roiz; Christophe Paupy; Xavier de Lamballerie
Journal:  Genes (Basel)       Date:  2018-08-21       Impact factor: 4.096

Review 4.  Serological cross-reactivity among common flaviviruses.

Authors:  Kai Rol Chan; Amni Adilah Ismail; Gaythri Thergarajan; Chandramathi Samudi Raju; Hock Chai Yam; Manikam Rishya; Shamala Devi Sekaran
Journal:  Front Cell Infect Microbiol       Date:  2022-09-15       Impact factor: 6.073

5.  Antibodies to the Novel Human Pegivirus 2 Are Associated with Active and Resolved Infections.

Authors:  Kelly E Coller; Michael G Berg; Matthew Frankel; Kenn Forberg; Rita Surani; Charles Y Chiu; John Hackett; George J Dawson
Journal:  J Clin Microbiol       Date:  2016-05-25       Impact factor: 5.948

Review 6.  Disease Resurgence, Production Capability Issues and Safety Concerns in the Context of an Aging Population: Is There a Need for a New Yellow Fever Vaccine?

Authors:  Kay M Tomashek; Mark Challberg; Seema U Nayak; Helen F Schiltz
Journal:  Vaccines (Basel)       Date:  2019-11-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.